Bluebird Bio Stock Is in Free Fall Weeks After a Landmark FDA Approval. Here ’s Why
Two weeks ago, bluebird bio secured Food and Drug Administration approval for its gene therapy for sickle cell disease, a significant milestone for the roughly 100,000 people in the U.S. who suffer from the condition.
Source: Reuters: Health - Category: Consumer Health News Source Type: news
More News: Food and Drug Administration (FDA) | Gene Therapy | Genetics | Health | Sickle Cell Anemia